, Cancer immunotherapies targeting the PD-1 signaling pathway, 2019.

M. C. Dalakas, Neurological complications of immune checkpoint inhibitors: what happens when you "take the brakes off" the immune system, Ther Adv Neurol Disord, vol.11, p.1756286418799864, 2018.

J. C. Kao, B. Liao, and S. N. Markovic, Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies, JAMA Neurology, vol.74, issue.10, p.1216, 2017.

S. Feng, J. Coward, E. Mccaffrey, J. Coucher, P. Kalokerinos et al., Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors, Journal of Thoracic Oncology, vol.12, issue.11, pp.1626-1635, 2017.

J. Larkin, B. Chmielowski, and C. D. Lao, Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis, Oncologist, vol.22, issue.6, pp.709-718, 2017.

J. Haanen, F. Carbonnel, and C. Robert, Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup ?, Annals of Oncology, vol.28, issue.suppl_4, pp.119-142, 2017.

S. Cuzzubbo, F. Javeri, and M. Tissier, Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature, European Journal of Cancer, vol.73, pp.1-8, 2017.

M. Touat, D. Talmasov, R. D. Psimaras, and D. , Neurological toxicities associated with immune-checkpoint inhibitors, Curr Opin Neurol, vol.30, issue.6, pp.659-668, 2017.

L. Spain, G. Walls, and M. Julve, Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature, Ann Oncol, vol.28, issue.2, pp.377-385, 2017.

E. Arriola, M. Wheater, and I. Galea, Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC, Journal of Thoracic Oncology, vol.11, issue.9, pp.1511-1521, 2016.

Y. Toi, S. Sugawara, and J. Sugisaka, Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer, JAMA Oncol, 2018.

J. R. Brahmer, C. Lacchetti, and B. J. Schneider, Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline, J Clin Oncol, vol.36, issue.17, pp.1714-1768, 2018.